ANGLE PLC says Nature Medicine journal highlights Parsortix's role in cancer breakthrough

(11:47)

ANGLE PLC’s new approach to Cancer diagnostics with Parsortix - One2One Investor Forum

(32:20)

ANGLE, PLC., (OTCQX: ANPCY) (AIM: AGL)

(14:38)

ANGLE PLC: Proactive One2One Virtual Conference

(32:41)

ANGLE, PLC., (OTCQX: ANPCY) (AIM: AGL)

(34:27)

ANGLE PLC – a small British company changing the world in cancer

(23:24)

ANGLE plc (AGL) - Andrew Newland, CEO and Ian Griffiths, CFO

(37:18)

ANGLE plc’s Parsortix a “game-changer” for prostate cancer detection, says CEO

(8:5)

ANGLE plc's Parsortix device plays critical role in ground-breaking new cancer research

(9:8)

ANGLE plc hails major breakthrough for Parsortix

(4:52)

ANGLE plc’s Parsortix a “game-changer” for prostate cancer detection, says CEO

(8:5)

ANGLE PLC presents at the Proactive One2One Investor Conference - January 11th

(32:30)

ANGLE PLC sees big opportunities in non-invasive prenatal testing

(9:29)

ANGLE PLC boss 'absolutely delighted' with results from pelvic mass study

(5:45)

ANGLE plc Presentation to Biotech Showcase Jan21

(30:47)

ANGLE plc makes key milestone with CE Mark

(4:52)

ANGLE PLC opens up potential route to market for Parsortix platform

(5:26)

Automated RNA extraction and DNA isolation technologies from QIAGEN

(3:3)

Bloomberg Turnaround: AstraZeneca

(24:7)

GSK – Our story

(3:57)

ANGLE plc Audio Interview 13 May 2013 Interim Results for the year ended 31 October 2013

(5:36)